SYNAPTEX, LLC

Biotech

Water-soluble small molecule (DDQ) that reduces amyloid beta and Drp1 levels and prevents their abnormal interaction in Alzheimer's disease neurons

Grants
$250K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.$249,507
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3324Cgenetech, Inc.——
3325HSIRI THERAPEUTICS——
3326Grit Bio Inc——
3327SYNAPTEX, LLC——
3328SURFACE BIOADVANCES, INC.——
3329LoQus23 Therapeutics——
3330ONCOSYNERGY, INC.—$27M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.